MatriClone™ And Clinical Manufacturing Grade Laminin: Accelerating Novel Cell Therapies To Market

Induced pluripotent stem cells (iPSCs) offer remarkable potential to differentiate into any cell type within the human body, presenting promising avenues for advancing the development of new cell therapies. However, their pluripotent potential is at risk without the support of essential components from the basement membrane.

MatriClone and Clinical Manufacturing Grade Laminin contain the recombinant laminin-511 E8 fragment that is crucial for growing and maintaining iPSCs. Together, these matrices offer an optimal solution for streamlining both the process development and manufacturing of novel iPSC therapies.